semaglutide weight loss medication Novo Nordisk's weight-loss pill wins FDA approval Semaglutide (wegovy) for Weight Loss

A Phase III, Multicentre, Randomised, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutanenous Bioresorbable CUV1647 Implants in Patients With Erythropoietic Protoporphyria (EPP) (Report)

The studys methodology and findings revealed data points: Among 710 type 2 diabetes patients, 17 semaglutide users developed NAION versus only 6 non-users, despite similar baseline characteristics In the weight loss cohort of 979 patients, NAION occurred in 20 semaglutide users compared to 3 in the control group Cumulative NAION incidence over 36 months reached 8.9% for diabetic semaglutide users versus 1.8% for non-GLP-1 medications Weight loss patients showed 6.7% NAION incidence with semaglutide versus 0.8% without Manual chart review by neuro-ophthalmology specialists ensured diagnostic accuracy often lacking in larger database studies Risk persisted after controlling for known NAION risk factors including age, sex, hypertension, and sleep apnea The biological plausibility of semaglutide-induced NAION stems from multiple proposed mechanisms that researchers continue investigating

2,4,6 The wide expression of these receptors suggests possible roles beyond glucose-lowering

[DOI] [PMC free article] [PubMed] [Google Scholar] 251.Suzuki K., Kim K.S., Bae Y.H

Health Canada expanded upon a June alert, warning the public not to purchase two additional unauthorized products being sold on Quadragen and Advanced Researchs websites

This reflects a more balanced view of potential aspiration risks against proven therapeutic benefits, especially for diabetes and cardiovascular care [11, 12]